Novel antithrombotic antibodies

• Main Authors: SUN TIANYAO, FAN XUEMEI, LIU JUNLING
• Format: Patent
• Language: Chinese; English
• Published: 09.12.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The invention provides a novel anti-thrombotic antibody, which takes FIXa as a target point, has unique performance, specifically targets a binding site of a blood coagulation factor FIXa and FVIIIa, reduces the formation of an FVIIIa-FIXa compound, and blocks the conversion from FX to FXa, so that the novel anti-thrombotic antibody plays an anti-thrombotic role. The antibody provided by the invention has proper antithrombotic performance, has a large effective treatment concentration window, but does not increase the risk of bleeding; the requirements of moderately resisting thrombus and effectively avoiding bleeding caused by excessive action in clinical application can be met. The invention also discloses a method for screening drugs by taking the FIXa-FVIIIa binding site as a target spot. 本发明提供了新型抗栓抗体，该抗体以FIXa为靶点且具有独特性能，其特异性靶向凝血因子FIXa与FVIIIa的结合位点，减少FVIIIa-FIXa复合物形成，阻断FX向FXa的转化，从而发挥抗栓作用。本发明的抗体具有合适的抗栓性能，有效治疗浓度窗口较大、但不增加出血风险；可实现临床应用中对于适度抗栓及有效避免过度作用导致出血问题的需求。本发明还揭示以FIXa-FVIIIa结合位点为靶点的筛选药物的方法。